✦ LIBER ✦

Response to Interferon Alfa-2b Therapy in Multitransfused Children with Beta-thalassemia and Chronic Hepatitis C

✍ Scribed by I. Spiliopoulou; M. Repanti; S. Katinakis; A. Karana-Ginopoulou; D. A. Papanastasiou

Publisher: Springer
Year: 1999
Tongue: English
Weight: 61 KB
Volume: 18
Category: Article
ISSN: 0934-9723
DOI: 10.1007/s100960050383

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant interferon-alfa therapy in c

Recombinant interferon-alfa therapy in children with chronic hepatitis C

✍ Flavia Bortolotti; Raffaella Giacchino; Pietro Vajro; Cristiana Barbera; Carlo C 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 642 KB

r-interferon alfa–2b/ribavirin combined

r-interferon alfa–2b/ribavirin combined therapy followed by low-dose r-Interferon alfa-2b in chronic hepatitis C interferon nonresponders

✍ A. Perasso; G. Testino; F. Ansaldi; V. Venturino; G.C. Icardi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 30 KB 👁 2 views

Predictors of a sustained beneficial res

Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C

✍ Hari S. Conjeevaram; James E. Everhart; Jay H. Hoofnagle 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB 👁 2 views

## Predictors of a Sustained Beneficial Response to Interferon Alfa Therapy in Chronic Hepatitis C Interferon alfa was first reported to have beneficial effects in chronic hepatitis C in the mid-l980s,' effects that were subsequently verified in multiple randomized controlled trials performed in

Response to higher doses of interferon a

Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial

✍ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi

Intrahepatic hepatitis C virus–specific

Intrahepatic hepatitis C virus–specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C

✍ David R. Nelson; Constantine G. Marousis; Tomoyoshi Ohno; Gary L. Davis; Johnson 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes (CTL) have been shown to play a role in host defense and pathogenesis of chronic HCV infection. Our aim was to test the hypothesis that intrahepatic HCV-specific CTL activity may impact subsequent response to interferon alfa (IFN-␣) therapy. O

Response to pegylated interferon alfa-2a

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4

✍ Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract The safety and efficacy of pegylated interferon (PEG‐IFN) alfa‐2a and ribavirin were studied among patients treated for genotype 4 chronic hepatitis C. Ninety‐five patients with chronic hepatitis C genotype 4 were treated with PEG‐IFN alfa‐2a (180 µg/week) plus ribavirin (≥11 mg/kg/day)